SpyGlass Pharma has raised $172.5 million in its initial public offering (IPO). The California-based company is developing implants that release medicines inside the eye over long periods using its SpyGlass drug delivery platform.
SpyGlass sold 10,781,250 shares of common stock at $16.00 per share, including the full exercise of the underwriters’ option to purchase an additional 1,406,250 shares. The shares began trading on the Nasdaq Global Select Market under the ticker symbol SGP on February 6, 2026, with the offering closing on February 9, 2026.
The company’s SpyGlass Platform combines approved drugs with small implants that gradually deliver treatment, with an initial focus on glaucoma and related eye conditions.
The company’s lead program, the BIM-IOL System, is an intraocular lens implant placed during routine cataract surgery. The lens contains small drug pads that release the glaucoma medication bimatoprost inside the eye over about three years.
Lowering eye pressure is the main way glaucoma is treated, but many patients struggle to use daily eye drops consistently, driving interest in longer-acting treatments.
Early clinical studies of the implant have shown sustained reductions in intraocular pressure. In a first-in-human feasibility trial, evaluable patients receiving the system experienced a mean intraocular pressure reduction of about 37% at 36 months, and most participants were able to discontinue topical pressure-lowering eye drops during that period.
The therapy is currently being studied in two Phase III clinical trials launched in July 2025. According to the company prospectus, the first patients had been randomized in the studies.
Each trial is expected to enroll about 400 patients across 45 clinical sites in the US, New Zealand and Asia. Enrollment is expected to finish in 2027. If successful, the company plans to pursue regulatory approval in the US through the FDA’s 505(b)(2) pathway, which allows sponsors to rely in part on existing data from previously approved medicines. The company expects to submit a New Drug Application (NA) in 2028.
The company is also developing a second implant designed to deliver bimatoprost without requiring cataract surgery. The ring-shaped implant is intended to be placed in the eye through a standalone procedure and may allow retreatment for patients who previously received the intraocular lens system. Animal studies are underway, and the company expects to begin first-in-human trials in 2026.
The company is also studying whether the platform could be used to treat other eye diseases, including age-related macular degeneration, postoperative eye care and chronic uveitis.
Because the implant is designed to be placed during routine cataract surgery, surgeons could use it as part of the same procedure.
Related: Generate Biomedicines IPO Raises $400M with Phase III Asthma Therapy in Pipeline
Implant-Based Approaches Expanding in Glaucoma Care
Demand for intraocular lenses has grown as cataract surgery volumes increase and manufacturers introduce newer lens designs intended to improve vision after surgery.
In February 2026, Avisi Technologies announced a $10.7 million Series A financing to support the SAPPHIRE clinical trial evaluating its VisiPlate glaucoma device. The implant is designed to reduce intraocular pressure by improving aqueous humor outflow. It uses multiple microchannels intended to maintain continuous drainage while limiting blockage. The SAPPHIRE study follows earlier investigation of the device in the VITA trial.
Myra Vision reported that the first patient had been treated in its US ADAPT clinical study evaluating the Calibreye surgical system. The multicenter study plans to enroll up to 70 patients with refractory glaucoma and includes a 12-month primary effectiveness endpoint. The implant is designed so physicians can adjust aqueous fluid outflow after surgery. This allows pressure control to be modified if needed.
Advances in cataract surgery technology are also shaping ophthalmology practice. In March 2026, Alcon shared that more than 175 million of its intraocular lenses have been implanted worldwide. The company’s portfolio includes presbyopia-correcting lenses designed to improve vision at multiple distances following cataract surgery.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN